AION Biosystems - Lightning Pitch

Why It Matters

By delivering real‑time infection alerts, Temp Shield could slash sepsis deaths and hospital stays, offering a scalable, CGM‑like solution that reshapes patient outcomes and reduces healthcare expenses.

Key Takeaways

• CEO's personal story drives mission to improve infection detection.
• Temp Shield aims to replace oral thermometers for early sepsis detection.
• Clinical study on 4,000 cancer patients shows 91% mortality reduction.
• Hospitalization rates dropped 79% using Temp Shield in trial.
• Goal: make infection monitoring as routine as CGM for diabetes.

Summary

The video is a lightning pitch by Sam Baron, CEO of AON Bios Systems, introducing Temp Shield – a wearable device designed to detect infections early, inspired by his father’s near‑fatal sepsis episode.

Baron argues that current infection monitoring relies on a century‑old oral thermometer, which often identifies sepsis too late. Temp Shield provides continuous temperature data, enabling clinicians to intervene before patients become critical. In a study of over 4,000 cancer patients, the device was associated with a 91% reduction in mortality and a 79% drop in inpatient hospitalizations.

He likens the technology’s potential impact to the continuous glucose monitor’s transformation of diabetes care, emphasizing that “everyone should have a Mayo‑clinic‑level chance to survive.” The pitch underscores both the personal urgency and the clinical evidence supporting the product.

If validated, Temp Shield could shift the standard of care for infection detection, lower hospital costs, and attract significant investment, positioning AON Bios Systems as a pioneer in proactive sepsis management.